Stocklytics Platform
Asset logo for symbol NAMS
NewAmsterdam Pharma Company N.V.
NAMS47
$16.40arrow_drop_up1.23%$0.20
Asset logo for symbol NAMS
NAMS47

$16.40

arrow_drop_up1.23%

AI Deep-Learning Forecast (NAMS)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

NewAmsterdam Pharma Company N.V. (NAMS) Stocklytics Forecast

NewAmsterdam Pharma Company N.V. (NAMS) is a pharmaceutical company that specializes in developing innovative medical solutions. With a strong track record of success and a dedicated team of researchers, NAMS is poised for growth in the coming years. The company has a diversified portfolio of products, ranging from therapeutics for rare diseases to over-the-counter medications. This diverse offering allows NAMS to capture a wide range of market opportunities and provide value to both patients and healthcare providers.
One of the key factors driving NAMS' future success is its commitment to research and development. The company invests heavily in cutting-edge technologies and collaborative partnerships to stay at the forefront of medical advancements. By leveraging artificial intelligence and machine learning, NAMS is able to identify promising drug candidates and accelerate the development process. This strategic approach not only reduces costs but also increases the likelihood of successful clinical trials and regulatory approvals.
add NewAmsterdam Pharma Company N.V. to watchlist

Keep an eye on NewAmsterdam Pharma Company N.V.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for NewAmsterdam Pharma Company N.V. (NAMS) stock?

Analysts have set a target price of $25.43 for NewAmsterdam Pharma Company N.V. (NAMS), based on forecasts from 7 analysts. The predicted price range extends from a high of $37 to a low of $19. This represents a potential increase of up to 125.61% and a decrease of 15.85% from the current price of $16.4. These forecasts are as of 2019 Sep 24.
help

What are the analyst ratings for NewAmsterdam Pharma Company N.V. (NAMS) stock?

Currently, there are no analyst ratings available for NewAmsterdam Pharma Company N.V. (NAMS), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for NewAmsterdam Pharma Company N.V. (NAMS) stock?

At present, there is no AI or machine-learning-based price prediction available for NewAmsterdam Pharma Company N.V. (NAMS) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media